<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090076</url>
  </required_header>
  <id_info>
    <org_study_id>ABOUND</org_study_id>
    <nct_id>NCT01090076</nct_id>
  </id_info>
  <brief_title>The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates- A Placebo Controlled Trial</brief_title>
  <official_title>The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates-A Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Changi General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aims to address the gap in the studies done and test the effects of a
      commercial mixture of 7 g of Arginine, 7 g Glutamine and 1.2 g HMB* twice a day on hard to
      heal pressure ulcers in an Asian patient cohort in an acute healthcare setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pressure ulcers are defined as areas of localised damage to the skin, muscle or underlying
      tissue, caused by shear, friction or unrelieved pressure, usually over bony prominences. They
      are associated with many health conditions that cause prolonged bed rest, immobility,
      inactivity or poor sensation and can significantly contribute to morbidity and mortality,
      particularly in the aged population. International prevalence rates range widely from 4.6%-
      83.6% due to methodological differences and classification systems. In Singapore, a study on
      the prevalence of pressure ulcers in 3 hospitals revealed a prevalence of 9% to 14%.

      Pressure ulcers often fail to heal in a timely and orderly manner, resulting in a chronic
      non-healing wound. Many intrinsic and extrinsic factors have been identified that can disrupt
      the wound healing processes of haemostasis, inflammation, proliferation, angiogenesis and
      remodelling. One of the factors gaining more interest for its impact on wound healing
      processes is nutritional status.

      Arginine is a semi-essential amino acid because even though the body normally makes enough of
      it, supplementation is sometimes needed during critical illness and severe trauma. There have
      been numerous research studies focusing on using arginine to enhance wound healing and
      pressure ulcer prevention. It is required for promotion of nitrogen balance, cell
      proliferation, T lymphocyte function and collagen accumulation. It also changes into nitric
      oxide, which is known for its vasodilatory and angiogenic properties.

      Glutamine is conditionally essential amino acid because it can be manufactured in the body,
      but under extreme physical stress the demand for glutamine exceeds the body's ability to make
      it. Adequate amounts of glutamine are generally obtained through diet alone because the body
      is also able to make glutamine on its own. Certain medical conditions, including injuries,
      surgery, infections, and prolonged stress, can deplete glutamine levels. Since glutamine
      plays a key role in the immune system, a deficiency in this nutrient can significantly slow
      the healing process.

      Beta-hydroxy-Beta methylbutyrate (HMB) is a metabolite of leucine, an essential amino acid.
      HMB supplementation was associated with increased muscle mass accretion. HMB appears to
      assert its effect via inhibiting muscle proteolysis and modulating protein turnover.

      Recently, arginine has been found to accelerate wound healing in combination with HMB and
      glutamine. It was shown that healthy subjects who are supplemented orally with arginine had a
      significant rise in plasma arginine and ornithine levels that led to enhanced rate of
      collagen synthesis. In another recent study, a HMB/Arginine/Lysine mixture increased protein
      turnover in elderly patients over a year long period. However, there is no known randomised
      controlled trial done on patients with chronic hard to heal wounds in acute healthcare
      settings.

      AIM To compare pressure ulcer healing rates in patients supplemented with a commercial
      HMB/Arginine/Lysine mixture (Abound) and standard high protein, high energy iso-nitrogenous
      medical nutritional supplements versus patients supplemented with only standard high protein,
      high energy iso-nitrogenous medical nutritional supplements.

      OUTCOME INDICATORS

        -  Percentage change in wound size (length, depth, area)

        -  Percentage change in proportion of viable wound tissue (Refer to wound data collection
           for details)

      The study will take on a comparative, randomised controlled trial design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% Viable Tissue</measure>
    <time_frame>weeks 1 to 2</time_frame>
    <description>-Percentage viable tissue after 2 weeks
The estimated change in proportion of viable and non-viable tissue was determined using area derived from planimetry via acetate tracings. The description of viable tissue was taken to mean granulating (red) or epithelising (pink) tissue, and non-viable tissue were taken as necrotic (black) or sloughy (green or yellow) tissue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% Wound Area Week 1</measure>
    <time_frame>week 0 to 1</time_frame>
    <description>Percentage change in wound area after week 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% Wound Area Week 2</measure>
    <time_frame>Weeks 1 to 2</time_frame>
    <description>Percentage change in wound area after week 2</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Pressure Ulcer</condition>
  <arm_group>
    <arm_group_label>Abound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator that contains none of the active ingredients</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)</intervention_name>
    <description>Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d</description>
    <arm_group_label>Abound</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pressure ulcers stage II, III or IV, non-healing admitted to Changi
             General Hospital for &gt; 2 weeks

          -  Patients who are able to attend outpatient follow-up appointments for dietary and
             wound review

        Exclusion Criteria:

          -  Age &lt; 21 years old

          -  Poorly controlled Diabetic Patients (HbA1c &gt;7.0%)

          -  Patients on Total Parenteral Nutrition

          -  Patients in MICU/ SICU/ Medically Unstable/ Palliative Care

          -  Patients with severe Sepsis

          -  Length of stay &lt; 2 weeks

          -  Patients who require fluid restriction &lt; 1L/d

          -  Patients on any other wound healing supplements (e.g. Zinc, Vitamin A and Vitamin C)

          -  Patients with lower extremity ulcers with untreated peripheral vascular disease

          -  Patients with deep tissue infection and/or requiring debridement of necrotic or
             sloughy tissue

          -  Patients unable to attend outpatient follow-up appointments

          -  Patients who cannot tolerate oral intake &gt; 70% EER and/or Fluid intake 30ml/kg BW

          -  Patients who require protein restriction

          -  Patients who are unable to give consent (absence of next-of-kin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alvin Wong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changi General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Baier S, Johannsen D, Abumrad N, Rathmacher JA, Nissen S, Flakoll P. Year-long changes in protein metabolism in elderly men and women supplemented with a nutrition cocktail of beta-hydroxy-beta-methylbutyrate (HMB), L-arginine, and L-lysine. JPEN J Parenter Enteral Nutr. 2009 Jan-Feb;33(1):71-82. doi: 10.1177/0148607108322403.</citation>
    <PMID>19164608</PMID>
  </reference>
  <reference>
    <citation>Smith HJ, Mukerji P, Tisdale MJ. Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss. Cancer Res. 2005 Jan 1;65(1):277-83.</citation>
    <PMID>15665304</PMID>
  </reference>
  <reference>
    <citation>Eley HL, Russell ST, Baxter JH, Mukerji P, Tisdale MJ. Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E923-31. Epub 2007 Jul 3.</citation>
    <PMID>17609254</PMID>
  </reference>
  <reference>
    <citation>Stechmiller JK, Childress B, Cowan L. Arginine supplementation and wound healing. Nutr Clin Pract. 2005 Feb;20(1):52-61. Review.</citation>
    <PMID>16207646</PMID>
  </reference>
  <reference>
    <citation>Benati G, Delvecchio S, Cilla D, Pedone V. Impact on pressure ulcer healing of an arginine-enriched nutritional solution in patients with severe cognitive impairment. Arch Gerontol Geriatr Suppl. 2001;7:43-7.</citation>
    <PMID>11431045</PMID>
  </reference>
  <reference>
    <citation>Desneves KJ, Todorovic BE, Cassar A, Crowe TC. Treatment with supplementary arginine, vitamin C and zinc in patients with pressure ulcers: a randomised controlled trial. Clin Nutr. 2005 Dec;24(6):979-87. Epub 2005 Nov 15.</citation>
    <PMID>16297506</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2010</study_first_posted>
  <results_first_submitted>February 13, 2013</results_first_submitted>
  <results_first_submitted_qc>May 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2013</results_first_posted>
  <last_update_submitted>June 14, 2013</last_update_submitted>
  <last_update_submitted_qc>June 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changi General Hospital</investigator_affiliation>
    <investigator_full_name>Alvin Wong</investigator_full_name>
    <investigator_title>Senior Dietitian</investigator_title>
  </responsible_party>
  <keyword>Pressure Ulcer Wound</keyword>
  <keyword>Specialized Amino Acid Mixture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Pressure Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>26 subjects were recruited between June 2010 to June 2011 and all subjects were inpatients of Changi General Hospital. 23 subjects completed the trial.</recruitment_details>
      <pre_assignment_details>Subjects were randomly assigned to either arm after an initial assessment by PI and wound nurses. There is no wash out period for this trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Abound</title>
          <description>Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo x 2 sachets/d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abound</title>
          <description>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB) : Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB) : Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.5" spread="18.4"/>
                    <measurement group_id="B2" value="74.3" spread="12.4"/>
                    <measurement group_id="B3" value="75.4" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>% Viable Tissue</title>
        <description>-Percentage viable tissue after 2 weeks
The estimated change in proportion of viable and non-viable tissue was determined using area derived from planimetry via acetate tracings. The description of viable tissue was taken to mean granulating (red) or epithelising (pink) tissue, and non-viable tissue were taken as necrotic (black) or sloughy (green or yellow) tissue.</description>
        <time_frame>weeks 1 to 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abound</title>
            <description>Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo x 2 sachets/d</description>
          </group>
        </group_list>
        <measure>
          <title>% Viable Tissue</title>
          <description>-Percentage viable tissue after 2 weeks
The estimated change in proportion of viable and non-viable tissue was determined using area derived from planimetry via acetate tracings. The description of viable tissue was taken to mean granulating (red) or epithelising (pink) tissue, and non-viable tissue were taken as necrotic (black) or sloughy (green or yellow) tissue.</description>
          <units>Percentage of viable tissue</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.06" spread="8.43"/>
                    <measurement group_id="O2" value="25.94" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>% Wound Area Week 1</title>
        <description>Percentage change in wound area after week 1</description>
        <time_frame>week 0 to 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abound</title>
            <description>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB) : Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB) : Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d</description>
          </group>
        </group_list>
        <measure>
          <title>% Wound Area Week 1</title>
          <description>Percentage change in wound area after week 1</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.37" spread="7.64"/>
                    <measurement group_id="O2" value="-13.68" spread="7.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.877</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>% Wound Area Week 2</title>
        <description>Percentage change in wound area after week 2</description>
        <time_frame>Weeks 1 to 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abound</title>
            <description>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB) : Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB) : Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d</description>
          </group>
        </group_list>
        <measure>
          <title>% Wound Area Week 2</title>
          <description>Percentage change in wound area after week 2</description>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.50" spread="10.11"/>
                    <measurement group_id="O2" value="-37.54" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Abound</title>
          <description>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB) : Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB) : Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of trial include small sample size and it was difficult to standardise wound care regimen as the pressure ulcers were of different stages and locations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mr Alvin Wong</name_or_title>
      <organization>Changi General Hospital</organization>
      <phone>68504627</phone>
      <email>alvin_wong@cgh.com.sg</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

